Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent

References

• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genetics. 2006;7(8):606–619. PMID: 16847462; doi: https://doi.org/10.1038/nrg1879.
   PubMed Web of Science ®Google Scholar
• Dey N, Sun Y, Carlson JH, Wu H, Lin X, Leyland-Jones B, De P. Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. Am J Cancer Res. 2016;6(4):714–746. PMID: 27186427.
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501. PMID: 12094235; doi: https://doi.org/10.1038/nrc839.
   PubMed Web of Science ®Google Scholar
• Vara JÁF, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treatment Rev. 2004;30(2):193–204. PMID: 15023437; doi: https://doi.org/10.1016/j.ctrv.2003.07.007
   PubMed Web of Science ®Google Scholar
• Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol. 1997;7(4):261–269. PMID: 9094314; doi: https://doi.org/10.1016/S0960-9822(06)00122-9.
   PubMed Web of Science ®Google Scholar
• Guri Y, Hall MN. mTOR signaling confers resistance to targeted cancer drugs. Trends Cancer. 2016;2(11):688–697. PMID: 28741507; doi: https://doi.org/10.1016/j.trecan.2016.10.006.
   PubMed Web of Science ®Google Scholar
• Ding J, Romani J, Zaborski M, MacLeod RAF, Nagel S, Drexler HG, Quentmeier H. Inhibition of PI3K/mTOR overcomes Nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. Plos One. 2013;8(12):e83510. PMID: 24349524; doi: https://doi.org/10.1371/journal.pone.0083510.
   PubMed Web of Science ®Google Scholar
• Sun Z, Li Q, Zhang S, Chen J, Huang L, Ren J, Chang Y, Liang Y, Wu G. NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation. OncoTargets Therapy. 2015;8:269–277. PMID: 25674002; doi: https://doi.org/10.2147/OTT.S62128.
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395–402. PMID: 17936563; doi: https://doi.org/10.1016/j.ccr.2007.08.030.
   PubMed Web of Science ®Google Scholar
• Park BH, Davidson NE. PI3 kinase activation and response to Trastuzumab therapy: What's neu with Herceptin resistance? Cancer Cell. 2007;12(4):297–299. PMID: 17936554; doi: https://doi.org/10.1016/j.ccr.2007.10.004.
   PubMed Web of Science ®Google Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Therapy. 2011;11(2):263–275. PMID: 21342044; doi: https://doi.org/10.1586/era.10.226.
   PubMed Web of Science ®Google Scholar
• Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, Stenzl A, Kuczyk MA. Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urologia Internationalis. 2008;80(4):372–377. PMID: 18587247; doi: https://doi.org/10.1159/000132694.
   PubMed Web of Science ®Google Scholar
• Carlo MI, Molina AM, Lakhman Y, Patil S, Woo K, Deluca J, Lee CH, Hsieh JJ, Feldman DR, Motzer RJ. A Phase Ib Study of BEZ235, a dual inhibitor of phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in patients with advanced renal cell Carcinoma. Oncologist. 2016;21(7):787–788. PMID: 27286790; doi: https://doi.org/10.1634/theoncologist.2016-0145.
   PubMed Web of Science ®Google Scholar
• Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Therapeutics. 2008;7(7):1851–1863. PMID: 18606717; doi: https://doi.org/10.1158/1535-7163.MCT-08-0017.
   PubMed Web of Science ®Google Scholar
• Yuan J, Mehta PP, Yin M-J, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Therapeutics. 2011;10(11):2189–2199. PMID: 21750219; doi: https://doi.org/10.1158/1535-7163.MCT-11-0185.
   PubMed Web of Science ®Google Scholar
• Pal I, Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacologica Sinica. 2012;33(12):1441–1458. PMID: 22983389; doi: https://doi.org/10.1038/aps.2012.72.
   PubMed Web of Science ®Google Scholar
• Britten CD, Adjei AA, Millham R, Houk BE, Borzillo G, Pierce K, Wainberg ZA, LoRusso PM. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Investigational New Drugs. 2014;32(3):510–517. PMID: 24395457; doi: https://doi.org/10.1007/s10637-013-0062-5.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Mancini A, Scarsella L, Colapietro A, Jitariuc A, Vitale F, Marampon F, Ricevuto E, Festuccia C. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models. Tumour Biol. 2016;37(1):341–351. PMID: 26219891; doi: https://doi.org/10.1007/s13277-015-3725-3.
   PubMedGoogle Scholar
• Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Research. 2008;68(19):8022–8030. PMID: 18829560; doi: https://doi.org/10.1158/0008-5472.CAN-08-1385.
   PubMed Web of Science ®Google Scholar
• Datta K, Bellacosa A, Chan TO, Tsichlis PN. Akt is a direct target of the phosphatidylinositol 3-kinase activation by growth factors, v-src and v-ha-ras, in sf9 and mammalian cells. J Biol Chem. 1996;271(48):30835–30839. doi: https://doi.org/10.1074/jbc.271.48.30835.
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9):729–734. PMID: 16915295; doi: https://doi.org/10.1038/nrc1974.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11(8):353–361. PMID: 16002336; doi: https://doi.org/10.1016/j.molmed.2005.06.007.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9–22. PMID: 17613433; doi: https://doi.org/10.1016/j.ccr.2007.05.008.
   PubMed Web of Science ®Google Scholar
• Wang Z, Huang Y, Zhang J. Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy. Cell Mol Biol Letters. 2014;19(2):233–242. PMID: 24728800; doi: https://doi.org/10.2478/s11658-014-0191-7.
   PubMed Web of Science ®Google Scholar
• Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. The efficacy of the novel dual PI3-Kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell Carcinoma. Clin Cancer Res. 2010;16(14):3628–3638. PMID: 20606035; doi: https://doi.org/10.1158/1078-0432.ccr-09-3022.
   PubMed Web of Science ®Google Scholar
• Cho D. Novel targeting of Phoshatidylinositol-3 Kinase and Mammalian Target of Rapamycin (mTOR) in renal cell carcinoma. Cancer J. 2013;19(4):311–315. PMID: 23867512; doi: https://doi.org/10.1097/PPO.0b013e31829d5cea.
   PubMed Web of Science ®Google Scholar
• Santoni M, Pantano F, Amantini C, Nabissi M, Conti A, Burattini L, Zoccoli A, Berardi R, Santoni G, Tonini G, et al. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochimica Et Biophysica Acta (BBA) – Rev Cancer. 2014;1845(2):221–231. PMID: 24480319; doi: https://doi.org/10.1016/j.bbcan.2014.01.007.
   PubMed Web of Science ®Google Scholar
• Conti A, Santoni M, Amantini C, Burattini L, Berardi R, Santoni G, Cascinu S, Muzzonigro G. Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Res Int. 2013;2013(12):1–9. PMID: 24093097; doi: https://doi.org/10.1155/2013/419176.
   PubMed Web of Science ®Google Scholar
• Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer. 2011;10(1):90. PMID: 21791089; doi: https://doi.org/10.1186/1476-4598-10-90.
   PubMed Web of Science ®Google Scholar
• Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P-A, Reinecke M, Ruprecht B, Petzoldt S, Meng C, et al. The target landscape of clinical kinase drugs. Science. 2017;358(6367):eaan4368. PMID: 29191878; doi: https://doi.org/10.1126/science.aan4368.
   PubMed Web of Science ®Google Scholar
• Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design. Acs Medicinal Chem Letters. 2012;4(1):91–97. PMID: 24900568; doi: https://doi.org/10.1021/ml300309h.
   PubMed Web of Science ®Google Scholar
• Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Translational Med. 2011;9:133–133. PMID: 21834980; doi: https://doi.org/10.1186/1479-5876-9-133.
   PubMed Web of Science ®Google Scholar